Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305489 | 0.92 | IRAK4 (0.72) | IRAK4MAP3K7KDRAURKBALK | |
| SCHEMBL10171322 | 0.85 | IRAK4 (0.60) | IRAK4MAP3K7KDRAURKBALK | |
| SCHEMBL349754 | 0.79 | IRAK4 (0.80) | IRAK4MAP3K7KDRAURKBALK | |
| SCHEMBL17320249 | 0.79 | IRAK4 (0.58) | IRAK4MAP3K7KDRAURKBALK | |
| SCHEMBL351417 | 0.78 | IRAK4 (0.78) | IRAK4MAP3K7ALKINSR | |
| SCHEMBL17320241 | 0.78 | IRAK4 (0.78) | IRAK4MAP3K7ALKINSR | |
| SCHEMBL19670084 | 0.78 | IRAK4 (0.78) | IRAK4MAP3K7ALKINSR | |
| SCHEMBL351304 | 0.78 | IRAK4 (0.51) | IRAK4MAP3K7KDRAURKBALK | |
| SCHEMBL10171268 | 0.77 | IRAK4 (0.60) | IRAK4MAP3K7KDRAURKBALK | |
| SCHEMBL350532 | 0.77 | IRAK4 (0.64) | IRAK4MAP3K7KDRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960372-B1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | claimed |
| EP-1960372-A1 | KINASE INHIBITORS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2007070872-A1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | MIDCAP FINANCIAL TRUST | 2016-01-28 | — | — | US | disclosed |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | MIDCAP FINANCIAL TRUST | 2016-01-28 | — | — | US | disclosed |
| EP-1960372-B1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | disclosed |
| US-9096542-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096542-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | IRAK4 239/4885MAP3K7 36/4885KDR 580/4885 |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | IRAK4 239/4885MAP3K7 36/4885KDR 580/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | IRAK4 293/4885MAP3K7 24/4885KDR 560/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | IRAK4 239/4885MAP3K7 36/4885KDR 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.